Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
21
mi
from 91732
Orange, CA
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
21
mi
from 91732
Orange, CA
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
37
mi
from 91732
Riverside, CA
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
37
mi
from 91732
Riverside, CA
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
356
mi
from 91732
San Francisco, CA
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
402
mi
from 91732
Santa Rosa, CA
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
402
mi
from 91732
Santa Rosa, CA
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2131
mi
from 91732
Jacksonville, FL
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2131
mi
from 91732
Jacksonville, FL
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2321
mi
from 91732
Miami, FL
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2321
mi
from 91732
Miami, FL
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2130
mi
from 91732
Orange Park, FL
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2130
mi
from 91732
Orange Park, FL
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2186
mi
from 91732
Orlando, FL
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2186
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2281
mi
from 91732
Stuart, FL
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2281
mi
from 91732
Stuart, FL
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2301
mi
from 91732
West Palm Beach, FL
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2301
mi
from 91732
West Palm Beach, FL
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1922
mi
from 91732
Atlanta, GA
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1922
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1730
mi
from 91732
Chicago, IL
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1647
mi
from 91732
Metairie, LA
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1647
mi
from 91732
Metairie, LA
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1401
mi
from 91732
Shreveport, LA
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1401
mi
from 91732
Shreveport, LA
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2301
mi
from 91732
Baltimore, MD
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2578
mi
from 91732
Boston, MA
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1934
mi
from 91732
Ann Arbor, MI
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1934
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1512
mi
from 91732
Fridley, MN
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1512
mi
from 91732
Fridley, MN
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1521
mi
from 91732
Maplewood, MN
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1521
mi
from 91732
Maplewood, MN
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1509
mi
from 91732
Minneapolis, MN
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1509
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1524
mi
from 91732
Rochester, MN
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2430
mi
from 91732
Hackensack, NJ
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2430
mi
from 91732
Hackensack, NJ
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2407
mi
from 91732
Morristown, NJ
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2407
mi
from 91732
Morristown, NJ
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2438
mi
from 91732
Albany, NY
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2438
mi
from 91732
Albany, NY
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2418
mi
from 91732
Amsterdam, NY
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2418
mi
from 91732
Amsterdam, NY
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2439
mi
from 91732
Hudson, NY
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2439
mi
from 91732
Hudson, NY
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2440
mi
from 91732
Latham, NY
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2440
mi
from 91732
Latham, NY
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2435
mi
from 91732
New York, NY
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2433
mi
from 91732
Rexford, NY
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2433
mi
from 91732
Rexford, NY
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2443
mi
from 91732
Troy, NY
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2443
mi
from 91732
Troy, NY
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2194
mi
from 91732
Chapel Hill, NC
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2194
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2100
mi
from 91732
Charlotte, NC
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2100
mi
from 91732
Charlotte, NC
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2198
mi
from 91732
Durham, NC
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2198
mi
from 91732
Durham, NC
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2122
mi
from 91732
Winston-Salem, NC
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2122
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1880
mi
from 91732
Cincinnati, OH
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2036
mi
from 91732
Cleveland, OH
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
829
mi
from 91732
Portland, OR
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
829
mi
from 91732
Portland, OR
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
820
mi
from 91732
Tualatin, OR
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
820
mi
from 91732
Tualatin, OR
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2121
mi
from 91732
Pittsburgh, PA
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2299
mi
from 91732
Sayre, PA
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2299
mi
from 91732
Sayre, PA
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2007
mi
from 91732
Easley, SC
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2007
mi
from 91732
Easley, SC
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2022
mi
from 91732
Greenville, SC
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2022
mi
from 91732
Greenville, SC
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2042
mi
from 91732
Spartanburg, SC
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2042
mi
from 91732
Spartanburg, SC
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1597
mi
from 91732
Memphis, TN
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1597
mi
from 91732
Memphis, TN
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1762
mi
from 91732
Nashville, TN
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1762
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
918
mi
from 91732
Amarillo, TX
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
918
mi
from 91732
Amarillo, TX
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1203
mi
from 91732
Bedford, TX
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1203
mi
from 91732
Bedford, TX
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1223
mi
from 91732
Dallas, TX
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1223
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1195
mi
from 91732
Fort Worth, TX
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1195
mi
from 91732
Fort Worth, TX
Click here to add this to my saved trials
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1229
mi
from 91732
Garland, TX
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1229
mi
from 91732
Garland, TX
Click here to add this to my saved trials